Christopher J DiMaio1, Frances Weis-Garcia2, Emilia Bagiella3, Laura H Tang4, Peter J Allen5. 1. Dr. Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, Mount Sinai Medical Center, New York, New York, USA. 2. Sloan-Kettering Institute, Monoclonal Antibody Core Facility, Memorial Sloan-Kettering Cancer Center, New York, New York, USA. 3. Department of Health Evidence and Policy, Icahn School of Medicine at Mount Sinai, New York, New York, USA. 4. Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, New York, USA. 5. Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York, USA.
Abstract
BACKGROUND AND AIMS: No reliable cyst fluid biomarkers exist that allow preoperative identification of patients with intraductal papillary mucinous neoplasms (IPMNs) and high-risk pathology. High-mobility group (HMG) A2 protein has been demonstrated to be a biomarker of dysplasia in IPMNs. It is unknown whether HMGA2 protein is present in the cyst fluid from IPMNs. The aims of this study were to determine whether HMGA2 protein is present in the cyst fluid of IPMNs and demonstrate whether HMGA2 protein concentration correlates with the degree of dysplasia. METHODS: Patients with surgically resected IPMNs and banked pancreatic cyst fluid were identified. Low-risk IPMNs (low-grade [LGD] or moderate dysplasia [MD]) and high-risk IPMNs (high-grade dysplasia [HGD] or invasive cancer) were identified. Pancreatic cyst fluid concentrations of HMGA2 protein were measured via enzyme-linked immunosorbent assay. RESULTS: Samples from 31 patients were analyzed. HMGA2 protein was detected in the cyst fluid of 30 of 31 specimens (97%). Median cyst fluid HMGA2 protein concentration (ng/mL) was as follows: LGD, 0.6 (interquartile range [IQR] 0.35-0.6); MD, 1.55 (IQR 0.65-2.7); HGD, 4.2 (IQR 1.7-9.2) (P < .05). The median HMGA2 protein concentration was significantly higher in the HGD group (4.2 ng/mL, IQR 1.7-9.2) compared with the concentration in the low-risk group (1.1 ng/mL, IQR 0.6-2.7, P = .03). CONCLUSION: HMGA2 protein is present in IPMN cyst fluid. Significantly higher concentrations of cyst fluid HMGA2 protein are found in IPMNs with HGD compared with lesions with LGD or MD. Cyst fluid concentrations of HMGA2 protein may thus serve as a biomarker to differentiate patients with high-risk IPMNs from those with low-risk IPMNs.
BACKGROUND AND AIMS: No reliable cyst fluid biomarkers exist that allow preoperative identification of patients with intraductal papillary mucinous neoplasms (IPMNs) and high-risk pathology. High-mobility group (HMG) A2 protein has been demonstrated to be a biomarker of dysplasia in IPMNs. It is unknown whether HMGA2 protein is present in the cyst fluid from IPMNs. The aims of this study were to determine whether HMGA2 protein is present in the cyst fluid of IPMNs and demonstrate whether HMGA2 protein concentration correlates with the degree of dysplasia. METHODS:Patients with surgically resected IPMNs and banked pancreatic cyst fluid were identified. Low-risk IPMNs (low-grade [LGD] or moderate dysplasia [MD]) and high-risk IPMNs (high-grade dysplasia [HGD] or invasive cancer) were identified. Pancreatic cyst fluid concentrations of HMGA2 protein were measured via enzyme-linked immunosorbent assay. RESULTS: Samples from 31 patients were analyzed. HMGA2 protein was detected in the cyst fluid of 30 of 31 specimens (97%). Median cyst fluid HMGA2 protein concentration (ng/mL) was as follows: LGD, 0.6 (interquartile range [IQR] 0.35-0.6); MD, 1.55 (IQR 0.65-2.7); HGD, 4.2 (IQR 1.7-9.2) (P < .05). The median HMGA2 protein concentration was significantly higher in the HGD group (4.2 ng/mL, IQR 1.7-9.2) compared with the concentration in the low-risk group (1.1 ng/mL, IQR 0.6-2.7, P = .03). CONCLUSION:HMGA2 protein is present in IPMN cyst fluid. Significantly higher concentrations of cyst fluid HMGA2 protein are found in IPMNs with HGD compared with lesions with LGD or MD. Cyst fluid concentrations of HMGA2 protein may thus serve as a biomarker to differentiate patients with high-risk IPMNs from those with low-risk IPMNs.
Authors: Salvatore Piscuoglio; Inti Zlobec; Pierlorenzo Pallante; Romina Sepe; Francesco Esposito; Arthur Zimmermann; Ioannis Diamantis; Luigi Terracciano; Alfredo Fusco; Eva Karamitopoulou Journal: Histopathology Date: 2012-02 Impact factor: 5.087
Authors: Lee Guan Lim; Sandeep Lakhtakia; Tiing Leong Ang; Charles K F Vu; Frederick Dy; Vui Heng Chong; Christopher J L Khor; Wee Chian Lim; Bhavesh Kishor Doshi; Shyam Varadarajulu; Kenjiro Yasuda; Jennie Y Y Wong; Yiong Huak Chan; Min En Nga; Khek Yu Ho Journal: Dig Dis Sci Date: 2013-01-13 Impact factor: 3.199
Authors: Robert Sedlack; Aboud Affi; Enrique Vazquez-Sequeiros; Ian D Norton; Jonathan E Clain; Maurits J Wiersema Journal: Gastrointest Endosc Date: 2002-10 Impact factor: 9.427
Authors: Ajay V Maker; Nora Katabi; Li-Xuan Qin; David S Klimstra; Mark Schattner; Murray F Brennan; William R Jarnagin; Peter J Allen Journal: Clin Cancer Res Date: 2011-01-25 Impact factor: 12.531
Authors: Lyndon V Hernandez; Girish Mishra; Christopher Forsmark; Peter V Draganov; John M Petersen; Steven N Hochwald; Stephen B Vogel; Manoop S Bhutani Journal: Pancreas Date: 2002-10 Impact factor: 3.327
Authors: William R Brugge; Kent Lewandrowski; Elizabeth Lee-Lewandrowski; Barbara A Centeno; Tara Szydlo; Susan Regan; Carlos Fernandez del Castillo; Andrew L Warshaw Journal: Gastroenterology Date: 2004-05 Impact factor: 22.682
Authors: Alexandra C Hristov; Leslie Cope; Marcelo Delos Reyes; Mansher Singh; Christine Iacobuzio-Donahue; Anirban Maitra; L M S Resar Journal: Mod Pathol Date: 2008-08-29 Impact factor: 7.842
Authors: N Abe; T Watanabe; Y Suzuki; N Matsumoto; T Masaki; T Mori; M Sugiyama; G Chiappetta; A Fusco; Y Atomi Journal: Br J Cancer Date: 2003-12-01 Impact factor: 7.640
Authors: Mohammad A Al Efishat; Marc A Attiyeh; Anne A Eaton; Mithat Gönen; Denise Prosser; Anna E Lokshin; Carlos Fernández-Del Castillo; Keith D Lillemoe; Cristina R Ferrone; Ilaria Pergolini; Mari Mino-Kenudson; Neda Rezaee; Marco Dal Molin; Matthew J Weiss; John L Cameron; Ralph H Hruban; Michael I D'Angelica; T Peter Kingham; Ronald P DeMatteo; William R Jarnagin; Christopher L Wolfgang; Peter J Allen Journal: Ann Surg Date: 2018-08 Impact factor: 12.969
Authors: Tatsuo Hata; Marco Dal Molin; Masaya Suenaga; Jun Yu; Meredith Pittman; Matthew Weiss; Marcia I Canto; Christopher Wolfgang; Anne Marie Lennon; Ralph H Hruban; Michael Goggins Journal: Clin Cancer Res Date: 2016-05-26 Impact factor: 12.531